BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
October 02, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from trial expected by end of 2025— RESEARCH...
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
September 30, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded...
BioCryst et l’Alliance pharmaceutique pancanadienne concluent avec succès les négociations au sujet de ORLADEYO (bérotralstat), un traitement oral à prise uniquotidienne pour la prévention des crises d’angio-œdème héréditaire
September 17, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RÉSERVÉ À UN PUBLIC CANADIEN TORONTO, 17 sept. 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq : BCRX) a annoncé aujourd’hui l’aboutissement des négociations avec l’Alliance...
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
September 17, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the...
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
September 06, 2024 02:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word...
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
September 05, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company’s new...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
BioCryst to Present at Upcoming Investor Conferences
August 22, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2024...
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...